This Is Too Hot For Xeris Biopharma Holdings Inc (NASDAQ: XERS), Let’s Take A Closer Look

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Most recently, Yahoo Finance reported about the stock as it publicized that Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

As a NASDAQ listed company, XERS falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $2.65 and fluctuated between $2.7850 as its day high and $2.6150 as its day low. The current market capitalization of Xeris Biopharma Holdings Inc is $366.02M. A total of 3.45 million shares were traded on the day, compared to an average of 1.78M shares.

Insider Activity

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, XERS has seen 3 BUY and 0 SELL insider trades, representing the acquisition of 43,639 and the disposition of 0 shares. Over the last 12 months, there were 18 BUYs and 0 SELLs from insiders. Insiders purchased 3,286,139 shares during that period but sold 0.

In the most recent transaction, SHERMAN JEFFREY W bought 5,400 shares of XERS for 1.87 per share on Nov 27. After the transaction, the Director now owns 5,400 company shares. In a previous transaction on Nov 20, Pieper Steven bought 28,000 shares at 1.95 per share. XERS shares that the insider owns now total 1,176,912.

Among the insiders who bought shares, HALKUFF DAWN acquired of 5,410 shares on Nov 20 at a per-share price of $1.84. This resulted in the Director holding 5,410 shares of XERS after the transaction. In another insider transaction, Shannon John Patrick Jr bought 30,769 shares at $1.64 per share on Nov 17. Company shares held by the insider now total 1,408,575.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, XERS has a high of $3.07 and a low of $1.11.

As of this writing, XERS has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.07 per share and a lower estimate of -$0.13. The company reported an EPS of -$0.14 in the last quarter, which was -7.70% lower than expectations of -$0.13.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. XERS’s latest balance sheet shows that the firm has $102.43M in Cash & Short Term Investments as of fiscal 2021. There were $88.07M in debt and $79.04M in liabilities at the time. Its Book Value Per Share was $0.03, while its Total Shareholder’s Equity was $95.23M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XERS is Buy with a score of 5.00.

Most Popular

Related Posts